Imagine reversing the course of conditions like Alzheimer's or multiple sclerosis, in which cells of the central nervous system stop working or die. Researchers at Johnson & Johnson are hot on the trail of innovative solutions that may do just that, preventing often-debilitating symptoms along the way.
Two new Johnson & Johnson initiatives aim to remove the obstacles people of color and the LGBTQIA+ community have historically faced in getting help with mental illness. The head of Janssen Neuroscience, Courtney Billington, explains why breaking these barriers is a priority—and a personal mission.
For World Schizophrenia Awareness Day, learn about how one inspiring young man with the condition is thriving despite the challenges—and how Johnson & Johnson is helping him and others like him to find new ways to manage their mental illness.
The exact cause of the disease is unknown, but there's a lot scientists do know about how it impacts nearly every part of the body. Scientists like Tatiana Scherz, M.D., who takes us on a guided journey of how the disease manifests—from your brain down to your toes.
It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.
Imagine being depressed and trying medication after medication—only to find none work. That's the plight of people with treatment-resistant depression. We look at this little-understood condition, and how researchers are working to crack its code.
With company leaders at the World Economic Forum in Davos this week, Johnson & Johnson's Chief Scientific Officer weighs in on the next great global healthcare challenge—and how we can all come together to help address it.